^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

NVG-111

i
Other names: NVG-111, NG I, NG II, NG III, NG IV, NVG 111, NVG111
Company:
Novalgen
Drug class:
CD3 agonist, ROR1 inhibitor
Related drugs:
11ms
Time Limited Exposure to a ROR1 Targeting Bispecific T Cell Engager (NVG-111) Leads to Durable Responses in Subjects with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL) (ASH 2023)
NVG-111 was administered in combination (N=8) with ibrutinib to subjects who had achieved a partial response to >1 year of ibrutinib therapy, or as monotherapy in subjects that progressed after covalent BTKi/B-cell lymphoma 2 inhibitor (BCL2i) (N=4). These data provide clinical proof of concept for selective targeting of ROR1 with a TCE leading to objective evidence of antitumor activity with encouraging response durability even in CLL patients known to have defective T cell function. The safety profile was consistent with the mechanism of action. Further evaluation of this promising molecule is ongoing.
Clinical
|
BCL2 (B-cell CLL/lymphoma 2) • CD8 (cluster of differentiation 8) • IL6 (Interleukin 6) • ROR1 (Receptor Tyrosine Kinase Like Orphan Receptor 1) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10)
|
Imbruvica (ibrutinib) • NVG-111
1year
NVG111-101: First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies (clinicaltrials.gov)
P1, N=90, Recruiting, NovalGen Ltd. | Phase classification: P1/2 --> P1
Phase classification
|
ROR1 (Receptor Tyrosine Kinase Like Orphan Receptor 1)
|
NVG-111
almost2years
Pre-Clinical Development of a First in Class Half-Life Extended T Cell Engager Targeting ROR-1 (ASH 2022)
We have generated a first in class ROR1 targeting half-life extended TCE that maintains the functional and biophysical properties of the clinically promising NVG-111. Our systematic evaluation suggests that careful selection of HLE format is critical for the development of a molecule with good yield, biophysical characteristics and potency. The selected ROR1 HLE-TCE supports weekly administration whilst maintaining potency at sub-nanomolar concentrations, properties which differentiate it from other TCEs in development.
Preclinical
|
ROR1 (Receptor Tyrosine Kinase Like Orphan Receptor 1)
|
NVG-111
almost2years
First-in-Human Phase I Trial of a ROR1 Targeting Bispecific T Cell Engager (NVG-111) in Combination with Ibrutinib or As Monotherapy in Subjects with Relapsed Refractory Chronic Lymphocytic Leukaemia (CLL) and Mantle Cell Lymphoma (MCL) (ASH 2022)
Early data shows that NVG-111 is generally well tolerated with a predictable and manageable safety profile. Promising evidence of efficacy was observed which appears to be durable in two subjects with MRD4 negative CR. Dose escalation is ongoing in combination or as monotherapy to determine the MTD/RP2D.
Clinical • P1 data • Combination therapy
|
BCL2 (B-cell CLL/lymphoma 2) • IL6 (Interleukin 6) • ROR1 (Receptor Tyrosine Kinase Like Orphan Receptor 1) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10)
|
MRD4 negative
|
Imbruvica (ibrutinib) • NVG-111
over2years
First-in-human phase I study of a ROR1-targeting bispecific T-cell engager (NVG-111) shows evidence of efficacy in patients with relapsed/refractory CLL and MCL. (ASCO 2022)
Five patients had CLL, and one had MCL, with all subjects remaining on ibrutinib whilst receiving NVG-111...This did not require tocilizumab or dose interruption except in one patient who developed transient, grade 3 immune effector cell–associated neurotoxicity syndrome-like symptoms (ICANS)... Early data with NVG-111 shows promising efficacy with a predictable and manageable safety profile.
Clinical • P1 data
|
ROR1 (Receptor Tyrosine Kinase Like Orphan Receptor 1)
|
Imbruvica (ibrutinib) • Actemra IV (tocilizumab) • NVG-111
over3years
First in Human Study of NVG-111 in Chronic Lymphocytic Leukaemia and Mantle Cell Lymphoma (clinicaltrials.gov)
P1/2, N=90, Recruiting, NovalGen Ltd. | Not yet recruiting --> Recruiting
Clinical • Enrollment open
|
ROR1 (Receptor Tyrosine Kinase Like Orphan Receptor 1)
|
NVG-111
over3years
Clinical • New P1/2 trial
|
ROR1 (Receptor Tyrosine Kinase Like Orphan Receptor 1)
|
NVG-111